Our Take
NICE approval opens access to a proven combination, but the decision rests entirely on MSD's KEYNOTE-A18 trial data with no independent reproduction cited.
Why it matters
Cervical cancer disproportionately affects underserved populations, and this marks the first immunotherapy option for locally advanced disease in England. Clinical teams can now offer patients a treatment that extended survival in the pivotal trial.
Do this week
Oncology teams: Review the KEYNOTE-A18 trial methodology and baseline chemoradiation outcomes before counseling stage III–IVA patients on pembrolizumab addition, so you can set realistic expectations on progression-free and overall survival gains.
NICE approves pembrolizumab plus chemoradiation for stage III–IVA cervical cancer
The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab (marketed as KEYTRUDA by MSD) in combination with external beam radiation therapy and brachytherapy as a treatment option for adults with untreated, locally advanced cervical cancer (LACC), classified as FIGO 2014 stage III–IVA. This marks the first immunotherapy approval for LACC in England.
The recommendation is based on efficacy data from KEYNOTE-A18, a phase 3 trial comparing pembrolizumab plus chemoradiation to standard chemoradiation alone (company-reported). The trial demonstrated improved progression-free survival and overall survival in the pembrolizumab arm. Pembrolizumab is licensed for use with external beam radiation followed by brachytherapy in patients with no prior definitive therapy.
MSD emphasized that cervical cancer disproportionately impacts women from underserved backgrounds and that an unmet need existed for additional treatment options in this population.
Access expansion in a high-burden population
Locally advanced cervical cancer carries significant morbidity and mortality, particularly in populations with limited access to early detection and standard oncologic care. NICE approval means English patients now have a clinically validated immunotherapy option integrated into the standard treatment pathway.
Alexandra Taylor, a consultant in clinical oncology at The Royal Marsden Hospital, described the approval as "an important milestone" that would give patients access to a treatment capable of improving long-term outcomes. Louise Broadbelt, a trial participant diagnosed with stage III cervical cancer in 2021, credited the trial with her continued survival and expressed hope that approval would benefit other patients facing the same diagnosis.
What oncology teams should verify
Clinical teams should examine the KEYNOTE-A18 trial design, patient inclusion criteria, and baseline chemoradiation outcomes to understand the magnitude of benefit pembrolizumab adds. Key questions: What was the progression-free survival improvement over standard care? What was the overall survival benefit? Were there subgroups (age, stage, HPV status) in which the combination performed better or worse?
Teams should also confirm licensing terms with MSD and NHS England to understand patient eligibility, sequencing with radiation, and any contraindications or monitoring requirements specific to the pembrolizumab-chemoradiation combination. NICE approval signals clinical value but does not replace site-level credentialing and protocol review before patient enrollment.